Search: id:"swepub:oai:lup.lub.lu.se:7c1fed99-8fba-4fec-848f-3c46b9d72c5b" >
Assessment of early...
Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab : Results from the Phase II PROMIX trial
-
- Kimbung, Siker (author)
- Lund University,Lunds universitet,Create Health,Annan verksamhet, LTH,Lunds Tekniska Högskola,Bröstcancer - prevention & intervention,Forskargrupper vid Lunds universitet,Other operations, LTH,Faculty of Engineering, LTH,Breast cancer prevention & intervention,Lund University Research Groups,Skåne University Hospital
-
- Markholm, Ida (author)
- Skåne University Hospital,Lund University
-
- Bjöhle, Judith (author)
- Karolinska University Hospital
-
show more...
-
- Lekberg, Tobias (author)
- Karolinska University Hospital
-
- Wachenfeldt, von Anna (author)
- Karolinska University Hospital
-
- Azavedo, Edward (author)
- Karolinska University Hospital
-
- Saracco, Ariel (author)
- Karolinska University Hospital
-
- Hellström, Mats (author)
- Karolinska University Hospital
-
- Veerla, Srinivas (author)
- Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital
-
- Paquet, Eric (author)
- Swiss Federal Institute of Technology
-
- Bendahl, Pär Ola (author)
- Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Individuell Bröstcancerbehandling,Forskargrupper vid Lunds universitet,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Personalized Breast Cancer Treatment,Lund University Research Groups,Skåne University Hospital
-
- Fernö, Mårten (author)
- Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Individuell Bröstcancerbehandling,Forskargrupper vid Lunds universitet,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Personalized Breast Cancer Treatment,Lund University Research Groups,Skåne University Hospital
-
- Bergh, Jonas (author)
- Karolinska Institutet,Karolinska University Hospital
-
- Loman, Niklas (author)
- Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Bröstcancer-genetik,Institutionen för kliniska vetenskaper, Lund,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Breastcancer-genetics,Department of Clinical Sciences, Lund,Skåne University Hospital
-
- Hatschek, Thomas (author)
- Karolinska Institutet,Karolinska University Hospital
-
- Hedenfalk, Ingrid (author)
- Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Bröst- och ovarialcancer,Forskargrupper vid Lunds universitet,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Breast and Ovarian Cancer Genomics,Lund University Research Groups,Skåne University Hospital
-
show less...
-
(creator_code:org_t)
- 2017-10-13
- 2018
- English.
-
In: International Journal of Cancer. - : Wiley. - 0020-7136 .- 1097-0215. ; 142:3, s. 618-628
- Related links:
-
http://dx.doi.org/10... (free)
-
show more...
-
https://onlinelibrar...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- Pathologic complete response (pCR) is a predictor for favorable outcome after neoadjuvant treatment in early breast cancer. Modulation of gene expression may also provide early readouts of biological activity and prognosis, offering the possibility for timely response-guided treatment adjustment. The role of early transcriptional changes in predicting response to neoadjuvant chemotherapy plus bevacizumab was investigated. One-hundred-and-fifty patients with large, operable and locally advanced HER2-negative breast cancer received epirubicin and docetaxel, with the addition of bevacizumab. Patients underwent tumor biopsies at baseline, after Cycle 2 and at the time of surgery. The primary end point, pCR, and its relation with the secondary endpoints event-free survival (EFS), overall survival (OS) and gene expression profiles, are reported. The pCR rate was 13% (95% CI 8.6-20.2), with significantly more pCRs among triple-negative [28% (95% CI 14.8-45.4)] than among hormone receptor positive (HR+) tumors [9% (95% CI 4.6-16.3); (OR=3.9 [CI=1.5-10.3])]. pCR rates were not associated with EFS or OS. PAM50 subtypes significantly changed after Cycle 2 (p=0.03) and an index of absolute changes in PAM50 correlations between these time-points was associated with EFS [HR=0.62 (CI=0.3-1.1)]. In univariable analyses, signatures for angiogenesis, proliferation, estrogen receptor signaling, invasion and metastasis, and immune response, measured after Cycle 2, were associated with pCR in HR+ tumors. Evaluation of changes in molecular subtypes and other signatures early in the course of neoadjuvant treatment may be predictive of pCR and EFS. These factors may help guide further treatment and should be considered when designing neoadjuvant trials.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- AIMS
- Breast cancer
- Neoadjuvant
- PAM50
- Pathological complete response
- Phase 2 trial
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database
- By the author/editor
-
Kimbung, Siker
-
Markholm, Ida
-
Bjöhle, Judith
-
Lekberg, Tobias
-
Wachenfeldt, von ...
-
Azavedo, Edward
-
show more...
-
Saracco, Ariel
-
Hellström, Mats
-
Veerla, Srinivas
-
Paquet, Eric
-
Bendahl, Pär Ola
-
Fernö, Mårten
-
Bergh, Jonas
-
Loman, Niklas
-
Hatschek, Thomas
-
Hedenfalk, Ingri ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
International Jo ...
- By the university
-
Lund University
-
Karolinska Institutet